NL1032286C2 - Benzoaat zout van 4- (5-methyl-oxazoloó4,5-b!pyridin-2-yl)-1,4-diaza-bicycloó3,2,2!nonaan. - Google Patents

Benzoaat zout van 4- (5-methyl-oxazoloó4,5-b!pyridin-2-yl)-1,4-diaza-bicycloó3,2,2!nonaan. Download PDF

Info

Publication number
NL1032286C2
NL1032286C2 NL1032286A NL1032286A NL1032286C2 NL 1032286 C2 NL1032286 C2 NL 1032286C2 NL 1032286 A NL1032286 A NL 1032286A NL 1032286 A NL1032286 A NL 1032286A NL 1032286 C2 NL1032286 C2 NL 1032286C2
Authority
NL
Netherlands
Prior art keywords
disease
treating
disorder
condition
salt
Prior art date
Application number
NL1032286A
Other languages
English (en)
Dutch (nl)
Other versions
NL1032286A1 (nl
Inventor
Jacob Duplantier Allen
Bruce Nelsen Rogers
Kenneth George Kraus
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NL1032286A1 publication Critical patent/NL1032286A1/nl
Application granted granted Critical
Publication of NL1032286C2 publication Critical patent/NL1032286C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL1032286A 2005-08-08 2006-08-08 Benzoaat zout van 4- (5-methyl-oxazoloó4,5-b!pyridin-2-yl)-1,4-diaza-bicycloó3,2,2!nonaan. NL1032286C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70660105P 2005-08-08 2005-08-08
US70660105 2005-08-08

Publications (2)

Publication Number Publication Date
NL1032286A1 NL1032286A1 (nl) 2007-02-09
NL1032286C2 true NL1032286C2 (nl) 2007-08-07

Family

ID=37398316

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1032286A NL1032286C2 (nl) 2005-08-08 2006-08-08 Benzoaat zout van 4- (5-methyl-oxazoloó4,5-b!pyridin-2-yl)-1,4-diaza-bicycloó3,2,2!nonaan.

Country Status (6)

Country Link
AR (1) AR055111A1 (es)
DO (1) DOP2006000185A (es)
NL (1) NL1032286C2 (es)
TW (1) TW200738734A (es)
UY (1) UY29731A1 (es)
WO (1) WO2007017750A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
CN107188900B (zh) * 2017-05-27 2019-09-06 北京师范大学 α7烟碱型乙酰胆碱受体的配体化合物及其应用
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086871A1 (en) * 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders

Also Published As

Publication number Publication date
DOP2006000185A (es) 2007-03-31
AR055111A1 (es) 2007-08-08
UY29731A1 (es) 2007-03-30
WO2007017750A1 (en) 2007-02-15
NL1032286A1 (nl) 2007-02-09
TW200738734A (en) 2007-10-16

Similar Documents

Publication Publication Date Title
US20080045512A1 (en) Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
NL1032286C2 (nl) Benzoaat zout van 4- (5-methyl-oxazoloó4,5-b!pyridin-2-yl)-1,4-diaza-bicycloó3,2,2!nonaan.
NL1030418C2 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
JP2021169481A (ja) アンドロゲン受容体の標的分解のための化合物および方法
CA3085942A1 (en) Aryl and heteroaryl substituted indole compounds
JP5584626B2 (ja) ２−アルキルアミノ−３−（アリールスルホニル）−シクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製の方法及び使用
TWI591063B (zh) 治療性化合物及相關使用方法
JP5584627B2 (ja) 置換されたシクロアルキル［ｅ又はｄ］ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
SK12472002A3 (sk) 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz
WO2014089913A1 (zh) 作为酪氨酸激酶抑制剂的并环化合物
WO2011063159A1 (en) Compounds and methods for kinase modulation, and indications therefor
CN103827090A (zh) 取代的喹啉及其作为药物的用途
CA2693915A1 (en) Pyrazolo[1,5-a]pyrimidine derivatives
AU2016233202A1 (en) Heterocyclic compounds useful as inhibitors of TNF
WO2017023902A1 (en) Cyclic compounds useful as modulators of tnf alpha
WO2022089398A1 (zh) 一种高活性的hpk1激酶抑制剂
WO2006051410A1 (en) Azabenzoxazoles for the treatment of cns disorders
JP5563559B2 (ja) ２−アミノ−３−スルホニル−テトラヒドロピラゾロ［１，５−ａ］ピリド−ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、調製のための方法及びその使用
AU2019289967A1 (en) OGA inhibitor compounds
JP5575663B2 (ja) 置換された２−アミノ−３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、その調製のための方法及び使用
KR20010102544A (ko) 카르바모일 테트라히드로피리딘 유도체
JP5690594B2 (ja) ３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用
US20060166974A1 (en) Azabenzoxazoles for the treatment of CNS disorders
RU2393158C1 (ru) ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2023059582A1 (en) Heterobifunctional compounds and their use in treating disease

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20070403

PD2B A search report has been drawn up
V1 Lapsed because of non-payment of the annual fee

Effective date: 20100301